Q2 2022 EPS Estimates for Alpine Immune Sciences, Inc. Increased by Wedbush (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Rating) – Research analysts at Wedbush increased their Q2 2022 EPS estimates for Alpine Immune Sciences in a report released on Tuesday, May 17th. Wedbush analyst R. Driscoll now expects that the biotechnology company will post earnings of ($0.23) per share for the quarter, up from their previous estimate of ($0.28). Wedbush has a “Outperform” rating and a $22.00 price objective on the stock. Wedbush also issued estimates for Alpine Immune Sciences’ Q3 2022 earnings at ($0.29) EPS, Q4 2022 earnings at ($0.33) EPS, FY2022 earnings at ($1.10) EPS, FY2023 earnings at ($1.94) EPS, FY2024 earnings at ($3.35) EPS and FY2025 earnings at ($3.58) EPS.

Other research analysts also recently issued reports about the stock. Oppenheimer reduced their price target on shares of Alpine Immune Sciences from $19.00 to $17.00 in a research report on Monday, March 7th. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of Alpine Immune Sciences in a research note on Friday, May 13th. Finally, Zacks Investment Research lowered Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, March 22nd.

Alpine Immune Sciences stock opened at $7.95 on Thursday. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average of $8.58 and a 200-day moving average of $9.94. Alpine Immune Sciences has a 52 week low of $6.00 and a 52 week high of $15.14.

Alpine Immune Sciences (NASDAQ:ALPNGet Rating) last issued its earnings results on Thursday, May 12th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). Alpine Immune Sciences had a negative return on equity of 46.87% and a negative net margin of 139.41%.

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC grew its stake in Alpine Immune Sciences by 223.1% in the third quarter. Barclays PLC now owns 4,747 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 3,278 shares in the last quarter. Citigroup Inc. grew its holdings in shares of Alpine Immune Sciences by 184.0% during the 4th quarter. Citigroup Inc. now owns 3,766 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,440 shares in the last quarter. Bank of America Corp DE boosted its holdings in Alpine Immune Sciences by 46.7% during the fourth quarter. Bank of America Corp DE now owns 4,944 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 1,573 shares in the last quarter. Strs Ohio acquired a new position in Alpine Immune Sciences during the fourth quarter worth $76,000. Finally, JPMorgan Chase & Co. raised its position in Alpine Immune Sciences by 23.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,697 shares during the last quarter. 77.00% of the stock is currently owned by institutional investors and hedge funds.

Alpine Immune Sciences Company Profile (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Recommended Stories

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.